Nasal cell test may predict cystic fibrosis drug success
NCT ID NCT03894657
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a test using cells from the nose can predict if the drug Orkambi® will improve lung function in people with cystic fibrosis. Researchers collected nasal cells from 91 participants before they started Orkambi® and measured how well the drug fixed the cells' function. The goal was to see if this lab test could serve as a biomarker for real-world breathing improvements.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker-Enfants Malades
Paris, Île-de-France Region, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smartphone tool may help cystic fibrosis patients survive the lung transplant waitlist
- Can a smartphone app reveal how CF treatments really work at home?
- Can a peer coach help young people take control of their chronic illness?
- Could a single antibiotic be enough for cystic fibrosis lung infections?
- Early use of powerful CF drugs may boost growth in young children
- Hands-On therapy may soothe cystic fibrosis pain without drugs